- Ọgwụgwọ
- Akaebe
- Neuroblastoma
- Tumor siri ike
- Akaebe
- TILS
- NK Cell Therapy
- Myasthenia Gravis (MG)
- Nnukwu ọrịa leukemia Lymphoblastic (B-ALL)
- Lupus Erythematosus System (SLE)
- Nnukwu ọrịa leukemia Lymphoblastic (T-ALL)
- Na-abụghị Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Na-ekesa nnukwu Lymphom B-cell
- B-lymphocytic leukemia
- Myeloma
Usoro ọgwụgwọ CAR-T maka Multiple Myeloma (MM)
Nchịkọta
Multiple Myeloma (MM) bụ ụdị ọrịa kansa nke na-emetụta mkpụrụ ndụ plasma na ụmị ọkpụkpụ. A maara ya maka ọdịdị dị mgbagwoju anya na nke na-agbanwe agbanwe, na-ebutekarị nlọghachi azụ na iguzogide ọgwụgwọ ọdịnala. Ọ bụ ezie na chemotherapy, transplants cell cell, na ọgwụ ọhụrụ emewo ka arụpụta ihe dị mma, ọtụtụ ndị ọrịa na-emesị nwee nguzogide ọgwụgwọ. CAR-T (Chimeric Antigen Receptor T-cell) ọgwụgwọ bụ ọgwụgwọ na-agbawa obi nke gosipụtara ihe ịga nke ọma dị ịrịba ama n'ịgwọ ọtụtụ myeloma na-emegharịghachi na refractory, na-enye ihe ngwọta dị mma maka ndị ọrịa nwere oke nhọrọ.
Kedu ihe bụ ọgwụgwọ CAR-T maka MM?
Usoro ọgwụgwọ CAR-T gụnyere imegharị mkpụrụ ndụ T nke onye ọrịa ka ọ mata ma wakpo mkpụrụ ndụ kansa nke ọma. Maka otutu myeloma, a na-emezi mkpụrụ ndụ CAR-T iji gbado anya BCMA (B-cell maturation antigen), protein dị n'elu sel myeloma. Mgbe emezichara ya site na mkpụrụ ndụ ihe nketa, a na-agbanyeghachi mkpụrụ ndụ T ndị a n'ime ahụ onye ọrịa, ebe ha na-achọ ma bibie mkpụrụ ndụ kansa, nke nwere ike ibute mgbaghara na ịdị ogologo oge.
Uru dị mkpa nke ọgwụgwọ CAR-T maka ọtụtụ Myeloma
- Ịrụ ọrụ dị elu na Nlaghachi azụ/Ntugharị MM: Usoro ọgwụgwọ CAR-T egosila nnukwu ihe ịga nke ọma na ndị ọrịa nwere nlọghachi azụ ma ọ bụ refractory multiple myeloma, na-enwetakarị mgbaghara zuru oke ma ọ bụ obere ọrịa fọdụrụnụ (MRD).
- Ezubere iche nkenkeSite n'ichebe BCMA, ọgwụgwọ CAR-T na-awakpo mkpụrụ ndụ myeloma kpọmkwem, na-echekwa anụ ahụ dị mma ma na-ebelata mmetụta ndị ọzọ ma e jiri ya tụnyere ọgwụgwọ nkịtị.
- Ahaziri ahaziri na nke ọhụrụUsoro ọgwụgwọ ahụ na-eji mkpụrụ ndụ T nke onye ọrịa, na-ahụ na atụmatụ ọgwụgwọ ahaziri nke ọma. Nke a na-enyekwa aka belata ihe ize ndụ nke ịjụ.
- Mgbaghara ogologo oge: Ọtụtụ ndị ọrịa na-agwọ ọrịa CAR-T na-enweta nzaghachi na-adịgide adịgide, yana ụfọdụ na-edobe mgbaghara ruo ọtụtụ afọ, ọbụlagodi mgbe ọgwụgwọ ndị ọzọ dara.
Usoro ọgwụgwọ
- Nchịkọta nke cell T: Nzọụkwụ mbụ gụnyere ịnakọta T-cell n'ọbara onye ọrịa site na iji leukapheresis, usoro yiri inye onyinye ọbara.
- Injinia T-cell: A na-eziga cell T-cell ndị a na ụlọ nyocha, ebe a na-emezigharị ha site na mkpụrụ ndụ ihe nketa iji gosipụta CAR kpọmkwem maka BCMA, na-eme ka ha nwee ike ịchọpụta na igbu mkpụrụ ndụ myeloma.
- Infusion nke mkpụrụ ndụ CAR-T: Mgbe mgbasawanye na ụlọ nyocha ahụ, a na-agbanyeghachi mkpụrụ ndụ T-engineer azụ n'ọbara onye ọrịa site na IV.
- Nleba anya na mgbake: Mgbe infusion gasịrị, a na-enyocha ndị ọrịa maka mmetụta ndị nwere ike ime dị ka cytokine release syndrome (CRS) ma ọ bụ neurotoxicity. Mmetụta ndị a na-ejikarị eme ihe site na enyemaka ahụike na nlekota.
Kedu ihe kpatara ịhọrọ ọgwụgwọ BIOOCUS CAR-T maka ọtụtụ Myeloma?
- Teknụzụ ọgbara ọhụrụ CAR-TBIOOCUS na-eji ọganihu kachasị ọhụrụ na teknụzụ CAR-T iji hụ na ọgwụgwọ kachasị mma na nsonaazụ kacha mma maka ndị ọrịa MM.
- Ọkachamara ahụike nke ụwa: Ndị ọkachamara anyị na hematology na immunotherapy na-enye nlekọta nkeonwe, na-ahụ na onye ọ bụla nwere ike ịnweta ọgwụgwọ kachasị mma maka ọnọdụ ha pụrụ iche.
- Ndekọ egwu egosipụtara: Anyị ejirila ọgwụgwọ CAR-T gwọọ ọtụtụ ndị ọrịa MM, ma ọtụtụ enwetala mgbaghara dị ịrịba ama, na-adịte aka.
- Nkwado zuru oke maka ndị ọrịa mba ụwaBIOOCUS na-enye nkwado zuru oke maka ndị ọrịa mba ụwa, na-eduzi gị site na usoro ọ bụla nke usoro ọgwụgwọ, site na ndụmọdụ mbụ na nlekọta nlekọta ọgwụgwọ.
Ihe akaebe na-ahụ maka ụlọ ọgwụ na ọnụego ihe ịga nke ọma
-
Ihe akaebe na-ahụ maka ụlọ ọgwụ na ọnụego ihe ịga nke ọma
Usoro ọgwụgwọ CAR-T maka otutu myeloma egosila nnukwu nsonaazụ na nnwale ụlọ ọgwụ na ntọala ụwa n'ezie. Karịsịa, egosila na ọ dị irè na ndị ọrịa laghachiri azụ ka ọtụtụ ahịrị ọgwụgwọ gasịrị, yana ụfọdụ na-enweta mgbaghara zuru oke ma ọ bụ ọnọdụ MRD-adịghị mma.
- Akụkọ onye ọrịa: iji CAR-T nweta mgbaghara ogologo oge maka ọtụtụ Myeloma
- Ọmụmụ ihe: Nzaghachi zuru oke na-eso ọgwụgwọ CAR-T na ọtụtụ Myeloma nlọghachite.
- Ịdị irè nke ọgwụgwọ CAR-T n'ịgwọ nlọghachi azụ / mgbagha ọtụtụ myeloma
Ọmụmụ ihe ọmụmụ ndị a na-egosi otú ọgwụgwọ CAR-T si na-agbanwe usoro ọgwụgwọ maka otutu myeloma, na-enye ndị ọrịa olileanya maka ịdị ndụ ogologo oge na ndụ ka mma.
Data ụlọ ọgwụ
Ngosipụta maka CD19+20CAR-T:Ndị ọrịa nwere lymphoma na-abụghị Hodgkin B-cell
| Ọnụego otu ọnwa CR | Ọnụego PR otu ọnwa | Otu ọnwa ma ọ bụ ọnụego | CRS≥3 | CRES≥3 |
| 71.95% (59/82) | 25.6 (21/82) | 97.55 (80/82) | 12.19% (10/82) | 0 |
Ngosipụta maka CD19+22CAR-T:Ọgwụgwọ nke CD19 nlọghachite na refractory nnukwu B-lymphocytic leukemia ndị ọrịa.
| Ọnụego otu ọnwa CR | Ọnụego PR otu ọnwa | Otu ọnwa ma ọ bụ ọnụego | CRS≥3 | CRES≥3 |
| 92.1% (35/38) | 7.9% (3/38) | 100% (38/38) | 15.79% (6/38) | 0 |
Ngosipụta maka BCMACAR-T:Ọgwụgwọ nke nlọghachi azụ na refractory multiple myeloma
| Ọnụego otu ọnwa CR | Ọnụego PR otu ọnwa | Otu ọnwa ma ọ bụ ọnụego | CRS≥3 | CRES≥3 |
| 72.41% (21/29) | 27.59% (8/29) | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.




